Kenneth Cusi

54.2k total citations · 26 hit papers
218 papers, 33.5k citations indexed

About

Kenneth Cusi is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Kenneth Cusi has authored 218 papers receiving a total of 33.5k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Epidemiology, 120 papers in Endocrinology, Diabetes and Metabolism and 56 papers in Molecular Biology. Recurrent topics in Kenneth Cusi's work include Liver Disease Diagnosis and Treatment (147 papers), Diet, Metabolism, and Disease (82 papers) and Metabolism, Diabetes, and Cancer (38 papers). Kenneth Cusi is often cited by papers focused on Liver Disease Diagnosis and Treatment (147 papers), Diet, Metabolism, and Disease (82 papers) and Metabolism, Diabetes, and Cancer (38 papers). Kenneth Cusi collaborates with scholars based in United States, Italy and United Kingdom. Kenneth Cusi's co-authors include Arun J. Sanyal, Zobair M. Younossi, Naga Chalasani, Michael Charlton, Joel E. Lavine, Elizabeth M. Brunt, Stephen A. Harrison, Ralph A. DeFronzo, Fernando Bril and Mary E. Rinella and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Kenneth Cusi

213 papers receiving 32.8k citations

Hit Papers

The diagnosis and management ... 2000 2026 2008 2017 2017 2012 2003 2012 2006 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
    2017 5.2k citations Zobair M. Younossi, Kenneth Cusi et al. Hepatology profile →
  2. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    2012 3.0k citations Zobair M. Younossi, Kenneth Cusi et al. Hepatology profile →
  3. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role ofPGC1andNRF1
    2003 1.6k citations Kenneth Cusi et al. profile →
  4. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
    2012 1.4k citations Zobair M. Younossi, Kenneth Cusi et al. profile →
  5. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
    2006 1.4k citations Stephen A. Harrison, Amalia Gastaldelli et al. profile →
  6. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
    2020 1.3k citations Kenneth Cusi, Vlad Ratziu et al. profile →
  7. Insulin resistance differentially affects the PI 3-kinase– and MAP kinase–mediated signaling in human muscle
    2000 856 citations Kenneth Cusi et al. profile →
  8. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
    2016 737 citations Kenneth Cusi, Beverly Orsak et al. profile →
  9. Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
    2012 681 citations Kenneth Cusi profile →
  10. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
    2018 619 citations Kenneth Cusi et al. profile →
  11. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
    2022 592 citations Kenneth Cusi, Diana Barb et al. Endocrine Practice profile →
  12. Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients
    2002 581 citations Kenneth Cusi et al. The Journal of Clinical Endocrinology & Metabolism profile →
  13. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    2012 429 citations Zobair M. Younossi, Kenneth Cusi et al. profile →
  14. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
    2018 405 citations Fernando Bril, Kenneth Cusi et al. Hepatology profile →
  15. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
    2015 393 citations Paola Portillo-Sánchez, Fernando Bril et al. The Journal of Clinical Endocrinology & Metabolism profile →
  16. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
    2021 357 citations Fasiha Kanwal, Jay H. Shubrook et al. profile →
  17. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    2022 328 citations Amalia Gastaldelli, Kenneth Cusi et al. profile →
  18. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
    2019 307 citations Amalia Gastaldelli, Kenneth Cusi profile →
  19. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
    2021 261 citations Kenneth Cusi et al. Hepatology profile →
  20. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
    2019 235 citations Fernando Bril, Diane Biernacki et al. Diabetes Care profile →
  21. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
    2020 231 citations Romina Lomonaco, Eddison Godinez Leiva et al. Diabetes Care profile →
  22. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
    2020 228 citations Kenneth Cusi et al. profile →
  23. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
    2024 69 citations Kenneth Cusi, Fasiha Kanwal et al. Hepatology profile →
  24. Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
    2024 59 citations Kenneth Cusi et al. Diabetes Spectrum profile →
  25. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
    2025 32 citations Diana Barb, Srilaxmi Kalavalapalli et al. Journal of Hepatology profile →
  26. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
    2025 25 citations Kenneth Cusi, Diana Barb et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenneth Cusi United States 75 23.9k 15.1k 8.6k 7.7k 7.4k 218 33.5k
Elisabetta Bugianesi Italy 77 27.9k 1.2× 12.9k 0.9× 5.4k 0.6× 10.6k 1.4× 4.8k 0.6× 298 33.3k
Brent A. Neuschwander‐Tetri United States 67 25.1k 1.0× 11.3k 0.8× 5.6k 0.6× 10.2k 1.3× 3.6k 0.5× 188 30.8k
Arthur J. McCullough United States 73 28.2k 1.2× 12.0k 0.8× 5.5k 0.6× 12.0k 1.6× 5.4k 0.7× 293 35.4k
Joel E. Lavine United States 60 24.3k 1.0× 11.8k 0.8× 3.4k 0.4× 9.8k 1.3× 3.5k 0.5× 144 28.4k
Christopher P. Day United Kingdom 86 23.0k 1.0× 9.9k 0.7× 4.1k 0.5× 10.2k 1.3× 3.1k 0.4× 186 31.1k
Quentin M. Anstee United Kingdom 73 19.7k 0.8× 7.9k 0.5× 4.0k 0.5× 8.9k 1.2× 3.0k 0.4× 254 23.9k
Mary E. Rinella United States 50 18.5k 0.8× 7.7k 0.5× 4.0k 0.5× 7.4k 1.0× 2.9k 0.4× 133 21.5k
Amalia Gastaldelli Italy 83 10.9k 0.5× 11.0k 0.7× 6.5k 0.8× 2.1k 0.3× 7.9k 1.1× 352 25.6k
Geoffrey C. Farrell Australia 76 19.9k 0.8× 6.9k 0.5× 4.7k 0.5× 10.0k 1.3× 2.6k 0.3× 213 26.1k
Paul Angulo United States 72 22.1k 0.9× 9.3k 0.6× 2.7k 0.3× 11.8k 1.5× 2.9k 0.4× 155 26.6k

Countries citing papers authored by Kenneth Cusi

Since Specialization
Citations

This map shows the geographic impact of Kenneth Cusi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Cusi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Cusi more than expected).

Fields of papers citing papers by Kenneth Cusi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Cusi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Cusi. The network helps show where Kenneth Cusi may publish in the future.

Co-authorship network of co-authors of Kenneth Cusi

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Cusi. A scholar is included among the top collaborators of Kenneth Cusi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Cusi. Kenneth Cusi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barb, Diana, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.. (2025). Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of Hepatology. 82(6). 979–991. 32 indexed citations breakdown →
2.
Younossi, Zobair M., Homie Razavi, Michael S. Sherman, et al.. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics. 61(9). 1467–1478. 8 indexed citations
3.
Cusi, Kenneth, et al.. (2024). Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know. Diabetes Spectrum. 37(1). 29–38. 7 indexed citations
4.
Cusi, Kenneth, et al.. (2024). Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies. Diabetes Spectrum. 37(1). 48–58. 35 indexed citations
5.
Sharma, Anu, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.. (2024). Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen. Obesity. 32(10). 1967–1974. 9 indexed citations
6.
Neeland, Ian J., et al.. (2023). Abstract #1395974: Achieving Waist Circumference Targets with Once Weekly Tirzepatide for the Treatment of Obesity. Endocrine Practice. 29(5). S35–S36. 1 indexed citations
7.
Castéra, Laurent & Kenneth Cusi. (2023). Diabetes and cirrhosis: Current concepts on diagnosis and management. Hepatology. 77(6). 2128–2146. 38 indexed citations
8.
Tang, Huilin, Stephen E. Kimmel, Steven M. Smith, et al.. (2022). Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care. 45(4). 1007–1012. 10 indexed citations
9.
Belfort‐DeAguiar, Renata, Romina Lomonaco, & Kenneth Cusi. (2022). Approach to the Patient With Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism. 108(2). 483–495. 10 indexed citations
10.
Mak, Lung‐Yi, Ed Gane, Christian Schwabe, et al.. (2022). A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. Journal of Hepatology. 78(4). 684–692. 52 indexed citations
11.
Kanwal, Fasiha, Jay H. Shubrook, Zobair M. Younossi, et al.. (2021). Preparing for the NASH epidemic: A call to action. Obesity. 29(9). 1401–1412. 11 indexed citations
12.
Gastaldelli, Amalia, Silvia Sabatini, Fabrizia Carli, et al.. (2021). PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver International. 41(11). 2659–2670. 74 indexed citations
13.
Lomonaco, Romina, Eddison Godinez Leiva, Fernando Bril, et al.. (2020). Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care. 44(2). 399–406. 231 indexed citations breakdown →
14.
Bril, Fernando, et al.. (2019). Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 104(8). 3327–3336. 74 indexed citations
15.
Bril, Fernando, Diane Biernacki, Srilaxmi Kalavalapalli, et al.. (2019). Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 42(8). 1481–1488. 235 indexed citations breakdown →
16.
Cusi, Kenneth, Fernando Bril, Diana Barb, et al.. (2018). Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 21(4). 812–821. 137 indexed citations
17.
Cusi, Kenneth, et al.. (2017). Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option. Journal of Investigative Medicine. 66(1). 7–10. 44 indexed citations
18.
Barritt, A. Sidney, Norman Gitlin, Samuel Klein, et al.. (2017). Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemporary Clinical Trials. 61. 33–38. 39 indexed citations
19.
Bril, Fernando, et al.. (2017). Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care. 41(1). 187–192. 34 indexed citations
20.
Cusi, Kenneth & Ralph A. De Fronzo. (1995). Treatment of NIDDM IDDM, and other insulin-resistant states with IGF-I: Physiological and clinicaI considerations. 3(2). 206–236. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabetta Bugianesi Breakdown of academic impact, for papers by Brent A. Neuschwander‐Tetri Breakdown of academic impact, for papers by Arthur J. McCullough Breakdown of academic impact, for papers by Joel E. Lavine Breakdown of academic impact, for papers by Christopher P. Day Breakdown of academic impact, for papers by Quentin M. Anstee Breakdown of academic impact, for papers by Mary E. Rinella Breakdown of academic impact, for papers by Amalia Gastaldelli Breakdown of academic impact, for papers by Geoffrey C. Farrell Breakdown of academic impact, for papers by Paul Angulo
Rankless by CCL
2026